Coherus BioSciences (NASDAQ:CHRS) Rating Lowered to “Sell” at StockNews.com

StockNews.com lowered shares of Coherus BioSciences (NASDAQ:CHRS) from a hold rating to a sell rating in a research report released on Friday morning.

CHRS has been the subject of a number of other reports. UBS Group reiterated a “neutral” rating and issued a $1.05 price target (down from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Coherus BioSciences in a report on Tuesday, April 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.26.

Coherus BioSciences Stock Performance

CHRS stock opened at $0.97 on Friday. Coherus BioSciences has a 52 week low of $0.66 and a 52 week high of $2.43. The company has a market capitalization of $111.95 million, a PE ratio of -12.07 and a beta of 1.01. The company’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $1.13.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Steph & Co. bought a new position in shares of Coherus BioSciences in the 4th quarter valued at $34,000. Bank of Montreal Can acquired a new stake in Coherus BioSciences in the fourth quarter valued at about $34,000. Intech Investment Management LLC bought a new position in Coherus BioSciences in the fourth quarter valued at about $38,000. CWM LLC raised its stake in Coherus BioSciences by 96.6% during the first quarter. CWM LLC now owns 49,793 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 24,468 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Coherus BioSciences by 97.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 15,214 shares during the last quarter. 72.82% of the stock is currently owned by institutional investors and hedge funds.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.